Crossmark

ASO Visual Abstract: Patient-Reported Outcomes 10 Years After Breast-Conserving Surgery for Early-Stage Breast Cancer

Published Online: 2024-09-25

Published Print: 2024-12

Authors

Dominici, Laura S.

Laws, Alison

Lagendijk, Mirelle

Grossmith, Samantha

Hughes, Melissa

Lin, Nancy

Mittendorf, Elizabeth A.

King, Tari A.
License Information

Text and Data Mining valid from 2024-09-25

Version of Record valid from 2024-09-25
More Information

Article History

First Online: 25 September 2024

Disclosure

: EAM reports compensated service on scientific advisory boards for Astra Zeneca, BioNTech, Merck, and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK reports speaker honoraria for Exact Sciences and compensated service on the FES Steering Committee, GE Healthcare, compensated service as faculty for PrecisCa cancer information service. MH reports speakers honoraria Exact Sciences, faculty PrecisCa cancer information service, compensated service FES-PET steering committee GE Healthcare.

Document is current